Patents by Inventor Huanan LIU

Huanan LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KCNQ potassium channel agonist, and preparation method therefor and use thereof
    Patent number: 10316008
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: June 11, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Yangming Zhang, Haining Hu, Haiyan Xu, Huanan Liu, Xiaoping Pi
  • KCNQ potassium channel agonists, method of preparation and method of use thereof
    Patent number: 10077245
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: September 18, 2018
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Yangming Zhang, Haining Hu, Haiyan Xu, Huanan Liu, Xiaoping Pi
  • LAMINATED TUBE AND METHOD FOR MANUFACTURING LAMINATED TUBE
    Publication number: 20180186114
    Abstract: There is provided a laminated tube including a first layer composed of a first material containing tungsten, a second layer formed on the outer peripheral surface of the first layer and composed of a second material having the property of causing no transformation accompanied by expansion when the second material is cooled from a temperature higher by 1,000° C. or more than the melting point of the second material down to 25° C., and a third layer formed on the outer peripheral surface of the second layer and composed of a third material having the property of being capable of causing a transformation accompanied by expansion when the third material is cooled from a temperature higher by 1,000° C. or more than the melting point of the third material down to 25° C.
    Type: Application
    Filed: June 30, 2016
    Publication date: July 5, 2018
    Inventors: Kourou HIRATA, Hirofumi TASHIRO, Huanan LIU
  • NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20180134677
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Yangming Zhang, Haining Hu, Haiyan Xu, Huanan Liu, Xiaoping Pi
  • NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF
    Publication number: 20170081301
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Application
    Filed: April 22, 2015
    Publication date: March 23, 2017
    Inventors: Fajun NAN, Min LI, Zhaobing GAO, Yangming ZHANG, Haining HU, Haiyan XU, Huanan LIU, Xiaoping PI